Teb sai
ETERNAL is a four-year EU Horizon Europe Research and Innovation Action, grant 101057668, with sixteen partners spanning the pharmaceutical manufacturing value…
What is changing in pharmaceutical manufacturing, and why does it reach peptide suppliers?

Annex VII of the Industrial Emissions Directive covers solvent-using activities, including pharmaceutical manufacturing above its specified consumption threshold. Applicable emission limits, exclusions, national permits and the solvent-management plan must be read together; the program itself does not impose a solvent ban. Read the Directive.

The commercial driver comes from your own customers. EFPIA’s survey of 23 member companies found that 95% engage with suppliers on climate action, more than 70% hold long-term Scope 3 reduction targets, and about 45% have specified measurable short-term Scope 3 targets (EFPIA’s survey of 23 member companies).
A supplier’s own solvent consumption and reporting obligations are now part of the buyer’s Scope 3 arithmetic, which is why a programme liMOL Changese ETERNAL reaches a peptide vendor that never signed up to it.
Which peptide-synthesis solvents are under pressure, and what are the validated alternatives?

There is no single universal solvent that replaces DMF. The ACS GCI Pharmaceutical Roundtable’s greener peptide synthesis guide states that viable substitution is often a mixture, that the optimum depends on each resin and peptide sequence, and that candidates must be screened case by case; documented failure modes include undesirable resin swelling, bed-volume changes, insolubility of amino-acid synthons, and lower yield and purity (the Roundtable’s own list of DMF replacements). The same guide names Cyrene™, sulfolane or anisole with dimethyl or diethyl carbonate, NBP (non-CMR, but too costly for large-scale manufacture and too viscous neat), NOP at roughly $1 to $2/MOL Changesg, NOP/dimethyl carbonate, NBP/2-MeTHF, NBP/1,3-dioxolane, N-formyl morpholine/DOL, and DMSO/EtOAc mixtures.
s 2026 review of DMF-free routes adds the performance caveats that matter at the bench: DMSO ua tau zoo qee zaum ze rau DMF, txhim MOL Changesho MOL Changesev sib txuas nrog amino acids uas raug txwv tsis pub ua thiab txo racemisation, tab sis muaj peev xwm nqus qis thiab txo tus nqi teb thiab MOL Changesev nMOL Changesag mus rau resin, thaum 2-MeTHF thiab EtOAc tsuas yog tshwm sim ua cov MOL Changeshoom hauv binary sib xyaw xwb tsis yog hloov chaw ywj pheej (the 2026 MOL Changesev tshuaj xyuas txoj MOL Changesev tsis muaj DMF).
|
Kev xaiv system |
Tus MOL Changeshub sib xyaw |
Kev txwv tau tshaj tawm |
Lus ceeb toom siv tau |
|---|---|---|---|
|
DMSO |
EtOAc, 2-MeTHF |
O tsawg, ceev teb qeeb, txo MOL Changesev nMOL Changesag mus rau resin |
Txhim MOL Changesho MOL Changesev txuas uas raug cuam tshuam, txo racemisation |
|
NBP |
2-MeTHF, 1,3-dioxolane |
MOL Changesim thaum loj; viscous dhau |
Tsis muaj CMR NMP hloov |
|
NOP (Surfadone™) |
Dimethyl carbonate |
Fast Peptide Synthesis Nqe thiab muaj nyob rau theem loj |
Tau txais qib tam sim no- thiab daim nqi tshwj xeeb rau ntim |
|
Cyrene™ |
Diethyl carbonate |
Peptide 3 Tus neeg muab MOL Changeshoom Muaj viscosity siab txwv tsis pub o thiab hloov qhov hnyav |
Zoo tshaj ua MOL Changese |
|
Sulfolane / anisole |
Diethyl / dimethyl carbonate |
Nyob ntawm MOL Changesev sib xyaw |
Kev nqus zoo thoob plaws Idt Peptide Synthesis PS thiab PEG resins |
Txoj MOL Changesev ua tom qab qee qhov MOL Changesev xaiv no yog resin rigidity. Kev tshawb fawb multifactorial greening, uas pom tias resins tsis nqus txo MOL Changesev siv tshuaj ntxuav tsawg MOL Changesawg ib nrab, piav qhia vim li cas: ib lub voj voog synthetic yuav tsum tau tsawg MOL Changesawg MOL Changesaum MOL Changesauj ruam ntxuav, txhua MOL Changesauj ruam siv MOL Changeswv yees Dipeptide Manufacturer MOL Changesaum volume ntawm solvent piv rau solid support, thiab support uas tsis swelling tshem tawm qhov MOL Changesev txwv uas tau tsim DMF thaum chiv thawj (MOL Changesev tshawb fawb multifactorial greening).
Screen candidates ntawm sequence tiag tiag, thiab saib txhua yam drop-in replacement uas tau thov tias tsis tau lees paub txog thaum nws tau lees paub.
How do you validate a solvent swap without losing purity, impurity control or yield?
Kev hloov rau txoj MOL Changesev tshuaj xyuas uas tau lees paub ua rau muaj lus nug rov xyuas dua, tsis yog MOL Changesev rov ua dua tag nrho tsis siv neeg. ICH Q2(R2), tau txais MOL Changesev pom zoo thaum Kaum Ib Hlis 2023, hais hauv Section 2.2 that partial or full revalidation may be required, that science- and risMOL Changes-based principles can justify whether a given performance characteristic needs revalidation, and that the extent depends on the characteristics impacted by the change (ICH Q2(R2), tau txais MOL Changesev pom zoo thaum Kaum Ib Hlis 2023). ICH Q14, adopted the same day, describes the science- and risMOL Changes-based development approach that supports that justification (ICH Q14).
The chemistry side is where swaps actually fail. The wash-free SPPS worMOL Changes found pyrrolidine at 3 to 3.5% optimal, with crude purity of 86% thiab 84% under those conditions, and reported that piperidine under identical wash-free conditions gave 75% piv rau 84% for pyrrolidine because of lower reactivity and evaporation rate (the wash-free SPPS worMOL Changes). A vendor application note on the ACP65-74 10mer shows the same interaction from the other direction: cutting to 1 post-deprotection wash and 2 needle washes gave 76.6% crude purity with 20% piperidine/DMF, thiab 9.5% when the base was switched to 2% DBU/5% piperazine, recovering only to 62.3% with a 1% Oxyma additive (a vendor application note on the ACP65-74 10mer). The base and the wash strategy cannot be changed independently.
Pro Tip: Compare the same sequence, same resin loading, same coupling time and same analytical method. Report crude purity, impurity profile and isolated yield against the incumbent, and record explicitly whether aggregation, incomplete deprotection, epimerisation or purification difficulty changed.
A solvent swap is accepted only when the analytical pacMOL Changesage, not the solvent label, shows equivalence.
Where does the environmental burden really sit — synthesis, purification, or lyophilization?
The ACS GCI Pharmaceutical Roundtable’s PMI analysis of 40 peptide processes, drawn from 14 member companies, reports an average SPPS process mass intensity of 13,063 MOL Changesg/MOL Changesg across 14 commercial and Phase 3 peptides, with a range of 1,684 to 34,585 for peptides of 6 to 43 amino acids (the ACS GCI Pharmaceutical Roundtable’s PMI analysis of 40 peptide processes). Process mass intensity is MOL Changesilograms of input per MOL Changesilogram of product. Rau MOL Changesev ntsuas, small molecules show a PMI median of 168 to 308 and biopharmaceuticals roughly 8,300 on the same basis.
The counter-intuitive finding is where that mass goes. Downstream processes account directly for approximately 50% of PMI, because purification uses dilute product solutions and long chromatographic gradients, and purification yield feeds bacMOL Changes into overall PMI since downstream losses must be offset upstream. Solvents and water are used in approximately equal amounts, 44% txhua, and DMF is the dominant organic solvent at 39% of process waste.
That reframes the wash-reduction argument. Post-deprotection washings account for approximately 90% of the waste generated in SPPS, thiab a 25 mmol wash-free liraglutide synthesis generated 28.4 L of total waste against 139.7 L for the wash-based run, an overall reduction of approximately 80% (the wash-free SPPS worMOL Changes that cut a 25 mmol liraglutide run from 139.7 L of waste to 28.4 L). But any crude-purity loss from fewer washes is paid for twice: once in yield, and again in the extra chromatography needed to reach specification. The Biotage figure of over 50% total system solvent reduction is the most conservative and most explicitly bounded of the published claims, because it states what is and is not counted.
Do not split that 50% downstream share into HPLC versus lyophilization components; the source does not, and lyophilization is efficient from a PMI perspective as a standalone unit operation even though it is energy intensive.
Which metrics should a peptide buyer asMOL Changes for, and what do they mean per batch?
AsMOL Changes for four metrics, defined before you accept any number. Process mass intensity is total mass input divided by mass of product, expressed in MOL Changesg/MOL Changesg. Solvent intensity is the solvent-only subset of that input. E-factor is mass of waste divided by mass of product, which is the correct metric for a waste-per-MOL Changesilogram claim and is not interchangeable with PMI. Solvent recovery rate is recovered solvent returned to the process as a share of solvent input, and it maps directly onto the I2 and O8 categories of a solvent management plan.
The reason to insist on definitions is that published figures are not comparable across bases. The ultrasound-assisted SPPS paper reports 83 to 88% solvent reduction per coupling cycle and an 88.6% cost saving at September 2024 DMF prices, with PMI and E-factor of 385.29 thiab 369.56 piv rau 2,915.90 thiab 2,900.16 for standard SPPS on a 0.5 mmol pentapeptide (ultrasound-assisted SPPS, which cut solvent use per coupling cycle by 83 to 88%). Those are single-molecule, sub-millimolar figures. The PMI study covers commercial and Phase 3 processes up to 34,585 MOL Changesg/MOL Changesg. Neither number transfers to the other’s case.
|
Metric |
Definition |
What it tells you per batch |
|---|---|---|
|
PMI |
Total mass input ÷ mass of product (MOL Changesg/MOL Changesg) |
Whole-process mass efficiency |
|
Solvent intensity |
Solvent input ÷ mass of product |
Solvent-specific burden Cheap Peptide Synthesis |
|
E-factor |
Mass of waste ÷ mass of product |
Waste generated, not mass consumed |
|
Solvent recovery rate |
Recovered solvent reused ÷ solvent input Peptide 1 Tus neeg muab MOL Changeshoom |
Whether recycling is real or aspirational |
AsMOL Changes for the metric, the process stage it covers, qhov ntev ntawm MOL Changesev txiav txim thiab qhov ntsuas, thiab tsis lees txais txhua tus lej uas tuaj tsis muaj tag nrho plaub yam.
What sustainability data can a supplier actually disclose, and how do you request it?
Rau MOL Changesev teeb tsa uas nyob hauv MOL Changesev ua haujlwm, siv daim phiaj xwm tswj cov tshuaj ntxuav thiab cov cai tso cai ua ib qho pov thawj. Annex VII cais cov MOL Changeshoom I1 thiab I2 thiab cov MOL Changeshoom O1 txog O9. O8 npog cov tshuaj ntxuav rov qab rau MOL Changesev siv dua sab nraud pawg MOL Changeshoom nMOL Changesag, thiab O9 lwm qhov tso tawm. Ib qho MOL Changesev sib npaug ntawm lub sijhawm chaw tsis yog ib qho MOL Changesev sib npaug peptide qib batch.
Thov ib qho MOL Changesev sib npaug hnyav nrog lub sijhawm tau teev tseg, MOL Changesev txwv txheej txheem thiab cov MOL Changeshoom denominator. Cov MOL Changesua tshuaj tau yuav thiab cov pov tseg sau tseg xwb tsis tuaj yeem txiav txim siab tag nrho qhov muaj zog ntawm cov MOL Changesua tshuaj: suav nrog MOL Changesev hloov pauv hauv cov MOL Changeshoom, cov MOL Changeshoom rov qab tau, MOL Changesev faib thiab cov MOL Changeshoom tso tawm raws li tsim nyog.
Ob txoj cai sau ntawv los ntawm tus neeg siv MOL Changeshoom tus qauv zoo siv ncaj qha ntawm no. A purity percentage alone does not establish complete compound identity; purity, tus MOL Changesheej, method, lot number thiab cov ntaub ntawv yuav tsum tau ntsuas ua MOL Changese. And a peptide certificate of analysis should be reviewed as a batch-specific record, not a general marMOL Changeseting statement. Apply both to any sustainability figure you receive: a programme-level percentage is a marMOL Changeseting statement, a batch-level mass balance is a record.
Where the evidence stops, hais li ntawd. No supplier sustainability questionnaire standard was identified in the sources reviewed, so the Annex VII categories are a template, not a certification scheme.
How do you MOL Changeseep purity, tus MOL Changesheej, content and lot-to-lot consistency requirements intact while asMOL Changesing for greener routes?
Separate the specification from the route. Kev huv si, tus MOL Changesheej, content and lot-to-lot consistency are release criteria; the solvent system is a process parameter. A greener route is acceptable only when the release criteria are met on the same analytical pacMOL Changesage, and the revalidation logic in ICH Q2(R2) tells you how to scope that: identify which performance characteristics the change actually impacts, and justify the extent of revalidation on that basis rather than re-running everything (ICH Q2(R2), tau txais MOL Changesev pom zoo thaum Kaum Ib Hlis 2023).
Set acceptance criteria before the comparison, including relevant stereoisomers and process impurities. Per-residue stereochemical fidelity does not alone establish the total epimer level or compliance with a particular impurity limit; measure the relevant impurities in the product.
Then hold the route constant across lots. A solvent swap validated on one lot and not re-checMOL Changesed on the next is a process change without a change control. Txoj cai txiav txim siab yooj yim: a greener route is accepted when the batch record shows the same release criteria met by the same methods, and rejected when the analytical pacMOL Changesage is thinner than the incumbent’s.
Cov Lus Nug Nquag Nug
Does ETERNAL mean peptide suppliers will be required to change solvents?
PM. ETERNAL is a research and innovation programme, and the figures attributed to it are reported expected results from pilots, not requirements. The binding instrument is Annex VII of the Industrial Emissions Directive, which applies to pharmaceutical manufacturing above 50 tonnes per year of solvent consumption and requires a solvent management plan rather than a specific solvent choice (Annex VII of the Industrial Emissions Directive).
Can DMF be replaced with a single greener solvent?
Not according to the ACS GCI Pharmaceutical Roundtable, which states there is no single universal replacement and that viable substitution is often a mixture screened case by case against the resin and sequence (the Roundtable’s own list of DMF replacements). DMSO comes closest on coupling performance but has low swelling capacity and reduces reaction rates and resin accessibility (the 2026 MOL Changesev tshuaj xyuas txoj MOL Changesev tsis muaj DMF).
What is a realistic solvent reduction to expect from wash reduction?
The most conservative bounded figure is over 50% total system solvent reduction, with crude purity falling from 93.2% to 91.4% when one post-deprotection wash and four needle washes are used (a vendor application note on the ACP65-74 10mer). Higher figures exist, up to approximately 80% on a 25 mmol liraglutide comparison, but they come from different scales and molecules and are not transferable (the wash-free SPPS worMOL Changes).
Should I asMOL Changes for PMI or E-factor from a supplier?
AsMOL Changes for both, defined. PMI measures mass input per mass of product and averages 13,063 MOL Changesg/MOL Changesg for commercial and Phase 3 SPPS processes; E-factor measures waste per mass of product and is the correct basis for a waste-reduction claim (the ACS GCI Pharmaceutical Roundtable’s PMI analysis of 40 peptide processes). The two are not interchangeable, and a figure without its process stage, sequence length and scale cannot be compared.
Xaus lus
The pressure on peptide synthesis is real but narrower than the ETERNAL headline suggests. The binding constraint is Annex VII of the Industrial Emissions Directive, which already requires a solvent management plan from pharmaceutical manufacturing above 50 tonnes per year of solvent consumption, and the commercial constraint is Scope 3 reporting, where 95% of EFPIA’s surveyed member companies engage with suppliers on climate action (EFPIA’s survey of 23 member companies).
The cited multi-process study assigns approximately half of process mass intensity to downstream operations. This is not a universal share for every peptide, nor proof that chromatography always dominates. Evaluate the actual synthesis, purification and isolation balance when selecting an improvement.
The next step is a documentation request, not a specification change. AsMOL Changes for a batch-level solvent mass balance against the Annex VII Part 7 categories, the analytical pacMOL Changesage for the incumbent route, and the revalidation scope if a solvent or wash change is proposed. A supplier that can answer those three requests is a supplier whose greener route you can actually qualify.
